KalVista Pharmaceuticals

Update in progress

KALV (NGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

KalVista Pharmaceuticals, Inc. is a biopharmaceutical company that develops oral therapies for rare diseases with unmet medical needs. Its lead candidate, EKTERLY, is a fast-acting, potent plasma kallikrein inhibitor for acute attacks of hereditary angioedema (HAE). The company is also advancing an orally disintegrating tablet program, KONFIDENT-KID for pediatric HAE, and KONFIDENT and KONFIDENT-S for adolescents and adults. HQ: Framingham, Massachusetts.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.34; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive